Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 26.12% | -215.62% | -363.30% | -4,845.95% | -135.39% |
| Total Depreciation and Amortization | 28.70% | -37.64% | 3.46% | 11.97% | -21.23% |
| Total Amortization of Deferred Charges | 470.00% | 418.18% | 790.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 99.32% | 594.51% | 775.17% | -98.45% | -267.50% |
| Change in Net Operating Assets | -71.85% | 195.46% | -604.85% | 53.06% | 40.60% |
| Cash from Operations | -65.41% | 181.08% | -633.33% | -393.30% | -71.79% |
| Capital Expenditure | 51.69% | 54.84% | 61.06% | 53.11% | 49.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 97.41% | -- | -- | -- |
| Cash from Investing | 74.89% | 93.04% | 902.80% | 53.11% | 2.78% |
| Total Debt Issued | -94.44% | -- | -- | -- | -- |
| Total Debt Repaid | -87.06% | -410.71% | -5,807.14% | 1.18% | -1.19% |
| Issuance of Common Stock | -65.00% | -- | 280.00% | -- | -41.18% |
| Repurchase of Common Stock | 75.00% | 66.67% | 99.19% | 96.64% | 99.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.67% | -118.75% | -1,485.99% | 85.11% | 421.00% |
| Foreign Exchange rate Adjustments | -236.36% | 210.00% | -185.71% | 33.33% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -94.05% | 99.32% | -339.64% | -51.39% | 133.08% |